Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

There are basically 4 parallel and distinct paths to approval.
Two in fibrosis and 2 in cirrhosis. The ones, maybe all, that will provide successful ph2 results will be followed by ph3's. So there might be an overlapping between ph2's and ph3's.
What Mento said though, is that LF ph2b trial could even turn out to be a pivotal trial (, hence trigger an AA without the need of a ph3 based on surrogate endpoint - (ie MELD score) - which will be a secondary enpoint in the LF ph2b trial (whilst primary endpoint will be a mix of clinical endpoints)